Prostaglandin E 2 (PGE 2 ) is an important lipid mediator of inflammation. However, whether and how PGE 2 regulates hepatic cholesterol metabolism remains unknown. We found that expression of the PGE 2 receptor, E prostanoid receptor 3 (EP3) expression is remarkably increased in hepatocytes in response to hyperlipidemic stress. Hepatocyte-specific deletion of EP3 receptor (EP3 I nflammatory responses are considered to lead to dysregulation of cholesterol metabolism.
I
nflammatory responses are considered to lead to dysregulation of cholesterol metabolism.
(1) They increase cholesterol accumulation by suppressing reverse cholesterol transport, (2) elevating hepatic cholesterol uptake, and stimulating de novo biosynthesis in the liver. (3) Moreover, inflammatory reactions alter the characteristics of high-density lipoprotein (HDL) from an anti-inflammatory lipoprotein to a proinflammatory form (4) and increase hepatic very low-density lipoprotein (VLDL) production while decreasing clearance of plasma VLDL as well. (5) On the other hand, cholesterol accumulation promotes inflammatory responses by enhancing Toll-like receptor signaling (6) and activating the inflammasome in inflammatory cells. (7) Therefore, inflammation and dysregulated cholesterol metabolism propel each other and play fundamental roles in the development and progression of metabolic diseases, including atherosclerosis.
Nonsteroidal anti-inflammatory drugs, including aspirin and Coxibs, exert analgesic and antipyretic effects mainly through inhibition of cyclooxygenase (COX)-derived prostaglandins (PGs). (8) High doses of aspirin have been found to decrease plasma cholesterol in patients with type 2 diabetes. (9) Mechanistically, aspirin promotes both reverse cholesterol transport and excretion of bile acids (BAs), probably through induction of lipoxygenase derivatives. (10) Moreover, Celecoxib, a selective COX-2 inhibitor, also decreases plasma cholesterol and attenuates hepatic lipid peroxidation in a rat model of hepatotoxicity (11) . However, genetic ablation of COX-1 or COX-2 does not reduce plasma cholesterol in hyperlipidemic mice (12) and even increased cholesterol levels in both the liver and plasma in mice under different circumstances. (13, 14) These divergent results are probably attributable to production of multiple bioactive PGs from COXs, which may have different effects on metabolic homeostasis. For instance, prostaglandin I 2 (PGI 2 ) and prostaglandin F 2a (PGF 2a ), but not thromboxane A 2 (TxA 2 ), promote hepatic gluconeogenesis, (15, 16) and prostaglandin D 2 (PGD 2 ) induces glycogenolysis in the liver, (17) whereas prostaglandin E 2 (PGE 2 ) suppresses glucagon-mediated gluconeogenesis. (18) In primary cultures of rat hepatocytes, the two-series PGs (PGD 2 , PGE 2 , and PGF 2a ) inhibit secretion of VLDL and triacylglycerol in an inflammatory-condition-dependent manner. (19, 20) In endometriotic cells, PGE 2 induces expression of steroidogenic genes for de novo synthesis of estradiol from cholesterol. (21) All PGs exert their physiological functions through binding to their specific receptors (DP1-2 for PGD 2 , EP1-4 for PGE 2 , IP for PGI 2 , TP for TxA 2 , and FP for PGF 2a ). However, whether and how PGs and their receptors regulate lipid metabolism in vivo remains unknown.
Here, we found that the PGE 2 receptor, E prostanoid receptor 3 (EP3), was markedly up-regulated in liver in hyperlipidemic mice. Unexpectedly, hepatic EP3 deficiency led to elevated cholesterol and exacerbated atherosclerosis in hepatocyte-EP3/ low-density lipoprotein receptor double-knockout
) mice. Moreover, we identified a cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA)/hepatocyte nuclear factor 4a/cholesterol 7a-hydroxylase (HNF4a/ CYP7A1) signaling axis that mediated impairment of BA biosynthesis and secretion in liver, leading to elevated plasma cholesterol and exacerbated atherosclerosis in EP3
hep-/-Ldlr 2/2 mice. Thus, our data suggest that activitation of hepatic EP3 receptor may confer promising therapeutic potential for treatment of hypercholesterolemia and atherosclerosis.
Materials and Methods
An expanded Materials and Methods section is available in the Supporting Information. . Abbreviation: Chol, cholesterol; TG, triglyceride.
MICE
Mice were housed in a virus-free, temperature-/ light-controlled animal facility under a 12-hour light/dark cycle. Animals were permitted ad libitum access to water and food. EP3 flox/flox mice (22) were backcrossed into a C57BL/6 background for 10 generations. EP3 flox/flox mice were mated with AlbuminCre transgenic mice (Jackson Laboratory, Bar hep1/1 and EP3 hep2/2 mice. GAPDH was used as a loading control (left). Cellular cholesterol content in primary hepatocytes isolated from male EP3 hep1/1 and EP3 hep2/2 mice (right). The cells were treated with or without H-89. (F) qRT-PCR analysis of ChIP products using CYP7A1 promoter-specific primers (n 5 6) (left). Gel electrophoresis image of regular PCR products using ChIP products (right). For A, E, and F, representative results from three independent experiments are shown. *P < 0.05 vs. 
ANALYSIS OF CHOLESTEROL AND TRIGLYCERIDE
Plasma cholesterol (Chol) and triglyceride (TG) were evaluated using commercial kits according to the manufacturer's instructions (Wako Life Sciences, Richmond, VA). Hepatic Chol and TG contents were assessed following lipid extraction as described. (16) Intracellular Chol levels were determined as described. (23) Distribution of Chol and TG among lipoproteins in pooled plasma (6 mice) were determined by fast-performance liquid chromatography (FPLC) on a Superose 6 column as described (24, 25) (GE Healthcare, Piscataway, NJ).
ANALYSIS OF TOTAL BAs
Total plasma BAs were measured according to the manufacturer's instructions (Diazyme, Richmond, VA). See the Supporting Information for details.
ANALYSIS OF AORTIC LESIONS
Atherosclerotic lesions were evaluated as described. (26) See the Supporting Information for details.
PRIMARY MOUSE HEPATOCYTE ISOLATION AND CELL CULTURE
Primary hepatocytes were isolated and cultured as described. (16) See the Supporting Information for details.
ADENOVIRUS GENERATION AND PURIFICATION
Recombinant adenoviral vectors expressing mouse CYP7A1 and HNF4a (wild type [WT] and S143A) were generated using the AdEasy Adenoviral System (Qibogene, Irvine, CA), according to the manufacturer's instructions. Mouse CYP7A1 and HNF4a were amplified from mouse liver complementary DNA by polymerase chain reaction (PCR) using KOD-PlusNeo High Fidelity DNA Polymerase (Toyobo, Tokyo, Japan). HNF4a point mutants were generated using the Fast mutagenesis system (TransGen, Beijing, China). The fidelity of all PCR cloning was verified by sequencing. Viruses were diluted in phosphatebuffered saline (PBS) and administrated at a dose of 10 7 plaque-forming units (PFU)/mL in a 12-well plate or by tail vein injection using 5 3 10 8 PFU/mL per mice. Mice were subjected to experiments 7 days after injections.
PKA ACTIVITY ASSAY
PKA activity was determined using the PepTag nonradioactive cAMP-dependent protein kinase assay kit (Promega, Madison, WI), according to the manufacturer's instructions. PKA activity was quantified by spectrophotometry (absorbance at 570 nm).
DELIVERY OF HNF4a PEPTIDE IN VIVO
Peptides with a TAT sequence (RKKRRQRRR) added at the NH 2 terminus to facilitate membrane penetration (27) were synthesized by GL Biochem (Shanghai, China): control, RKKRRQRRR; HNF4a P121-170, RKKRRQRRRFRAGMKKEAVQNER DRISTRRSSYEDSSLPSINALLQAEVLSQQITSP IS. Peptides were dissolved in PBS containing 0.5% bovine serum albumin (pH 7.0). Mice were intraperitoneally injected with control or P121-170 peptide (500 lg/kg/day) for 14 days. 
IN VITRO

STATISTICAL ANALYSIS
Data are presented as means 6 SEM. Analysis was performed with GraphPad Prism software (version 6; GraphPad Software Inc., San Diego, CA). Significance was assessed by an unpaired two-tailed t test, unless otherwise indicated. For all studies, values of P < 0.05 were considered statistically significant.
Results
HEPATIC EP3 DEFICIENCY ELEVATES PLASMA Chol AND AUGMENTS DIET-INDUCED ATHEROSCLEROSIS IN MICE
High-fat diet boosts PG generation in mouse liver. (16) In this study, all PG receptors were expressed at varying levels in liver, whereas only EP3 expression was up-regulated in response to WD feeding in mice (Fig. 1A) and in response to 25-OH Chol treatment in primary hepatocytes (data not shown), suggesting that EP3 might be involved in lipid homeostasis in liver. Indeed, hepatocyte-specific EP3 deficiency (EP3 hep-/-; Supporting Fig. S1A ) led to a significant elevation of plasma Chol without markedly influencing TG levels in both plasma and the liver (Fig. 1B) . Notably, on an low-density lipoprotein (LDL) receptor (LDLR)-deficient genetic background, EP3 deficiency in hepatocytes augmented WD-induced hypercholesterolemia, Chol production in liver, and fecal Chol secretion in both male and female mice ( Fig. 1C and Supporting Fig. S1B ). FPLC analysis confirmed that plasma Chol levels, including VLDL, LDL, and HDL Chol, were increased in WD-fed EP3 hep-/-Ldlr 2/2 mice ( Fig. 1D and Supporting Figs. S1C and S2). Moreover, en face atherosclerotic lesion area was strikingly increased in EP3 hep-/-Ldlr 2/2 than in Ldlr -/-mice (males, 6.4 6 0.5% vs. 13.7 6 1.3% at 12 weeks of WD; 25.4 6 1.4% vs. 32.6 6 2.9% at 24 weeks of WD; P < 0.05; females, 4.7 6 0.7% vs. 10.1 6 1.5% at 12 weeks of WD; 18.7 6 1.1% vs. 24.3 6 3.3% at 24 weeks of WD; P < 0.05; Fig. 1E and Supporting Fig. S1D Fig. 1F and Supporting Fig.  S1E ). In addition, expression of the macrophage surface marker, CD68, as a percentage of the total lesion area at the aortic root, was modestly increased in EP3 hep-/-Ldlr 2/2 mice (Supporting Fig. S3A,B ). There were no overt differences in other cellular and matrix components tested (a smooth muscle actin [a-SMA] and collagen I; Supporting Fig. S3A-D) in atherosclerotic plaques. In contrast, hepatocyte EP3 deletion had no observable effect on TG metabolism in mice (Supporting Fig. S4A-D) . These data demonstrated that EP3 hep-/-Ldlr 2/2 mice develop more atherosclerosis, probably as a consequence of aggravated hypercholesterolemia.
HEPATOCYTE-SPECIFIC EP3-DEFICIENT MICE HAVE REDUCED SYSTEMIC BA
Hepatic Chol homeostasis is maintained by coordinated regulation of uptake, endogenous biosynthesis, and de novo conversion to BAs. (28) We examined alterations in expression of key enzymes/genes involved in different cholesterol metabolic processes in hepatocyte EP3-deficient mice. Given that normal WT mice are quite resistant to atherosclerosis (29) and athero-prone genetic background (Ldlr 2/2 ) exacerbated hypercholesterolemia and atherosclerosis in EP3 2/2 mice (Fig. 2) Fig. S5A ). EP3 deficiency in hepatocytes did not influence Chol transport in liver and intestine (Supporting Fig. S5B,  C) . In addition, we did not detect notable alterations of key transcriptional factors involved in regulation of Chol metabolism, including farnesoid X receptor (FXR), HNF4a, liver receptor homolog-1 (LRH-1), and small heterodimer partner (SHP), in EP3 hep-/-Ldlr 2/2 mice (Supporting Fig. S5D,E) . Interestingly, among key enzymes for hepatic Chol degradation to BAs (Fig. 2A) , CYP7A1, CYP8B1, and CYP27A1 were down-regulated in liver in hyperlipidemic EP3
hep-/-Ldlr 2/2 mice (Fig. 2B and Supporting Fig. S6A-C) . Total BA levels in plasma, liver, and gallbladder and subsequent fecal BA excretion were significantly lower in EP3
hep-/-Ldlr 2/2 than in Ldlr -/-mice ( Fig. 2C and Supporting Fig. S6D ). Liquid chromatography/mass spectrometry analysis demonstrated that almost all BA species tested were reduced in EP3
hep-/-Ldlr 2/2 mice despite the majority of BAs being conjugated in plasma, liver, and gallbladder (Fig. 2D-F) . Taken together, these results indicated that hepatocyte EP3 deficiency-induced hypercholesterolemia may be attributed to dysregulation of oxidation of Chol to BAs in liver.
CYP7A1 OVEREXPRESSION ABOLISHES THE EFFECTS OF HEPATIC EP3 DEFICIENCY ON BAs AND Chol IN MICE
Next, adenovirus-expressing CYP7A1 was used to address whether suppression of CYP7A1 was responsible for the elevated cholesterol levels in EP3 hep-/-Ldlr 2/2 mice. Injections of adenovirusexpressing CYP7A1 raised liver CYP7A1 expression to similar levels in EP3 hep-/-Ldlr 2/2 mice, thereby blocking the suppressive impacts of hepatic EP3 deficiency (Fig. 3A) . Protein expression of CYP7A1 followed a similar trend (Fig. 3B) . Interestingly, overexpression of CYP7A1 also increased the gene and protein expression of CYP8B1, CYP27A1, and CYP7B1 to comparable levels in livers of EP3 hep1/1 Ldlr 2/2 and EP3 hep-/-Ldlr 2/2 mice (Fig. 3A,B) , likely because of increased availability of substrates for the other enzymes. However, forced expression of CYP27A1 failed to rescue the reduced expression of CYP7A1 in EP3 deficient hepatocytes (data not shown). CYP7A1 overexpression increased BA levels in plasma, liver, gallbladder, and feces to comparable levels in EP3 hep1/1 Ldlr 2/2 and EP3 hep-/-Ldlr 2/2 mice (Fig.  3C) . As a result, CYP7A1 overexpression abolished the suppressive effects of hepatic EP3 deficiency on BAs (Figs. 3C) . Moreover, CYP7A1 overexpression decreased plasma cholesterol and increased fecal cholesterol in both genotypes, eliminating the elevation of plasma and fecal Chol levels observed in EP3 hep-/-Ldlr 2/2 mice (Fig. 3D,E) . These results suggested that hepatic EP3 deficiency-mediated dysregulation of BA biosynthesis and hypercholesterolemia depends on decreased expression of CYP7A1 in liver.
EP3 DEFICIENCY INCREASES PKA-MEDIATED PHOSPHORYLA-TION OF HNF4a AND DECREASES CYP7A1 TRANSCRIPTION
Truncated human and mouse CYP7A1 promoters were constructed for luciferase assays in HepG2 and Hep1-6 cells, respectively (Fig. 4A) . Treatment with the EP3 inhibitor, L-798106, suppressed transcriptional activity of both the human and the mouse CYP7A1 promoters (Fig. 4B) . Deletion of the region from -1000 to -100 of the human CYP7A1 promoter did not affect L-798106-induced inhibition of transcriptional activity (Fig. 4B, left panel) . However, further deletion to 250 abolished the suppressive effects of L-798106, suggesting that the region between -50 and 2100 is key to the effects. Similarly, the region between 2100 and 2200 in the mouse promoter was identified as being crucial for suppressive effects (Fig. 4B, right panel) . This region has been reported as a BA response element containing a direct repeat separated by one nucleotide direct repeat 1 (DR1) for binding of HNF4a. (30) Mutations in the DR1 region also eliminated the suppressive effects of L-798106 on both the human and mouse CYP7A1 promoters (Fig. 4C,D) , further demonstrating its importance. To further determine the effect of HNF4a on the regulation of CYP7A1expression, small interfering RNA (SiRNA)-mediated knockdown of HNF4a was carried out in human (HepG2 and LO2) and mouse (Hep1-6 and AML12) cells (Fig. 4E) . Knockdown of HNF4a abolished the suppressive effects of L-798106 on both the human and mouse CYP7A1 promoters (Fig. 4F) . These results suggested that hepatic EP3 regulates expression of CYP7A1 through HNF4a.
Previous studies have shown that EP3 couples to the G ai protein, which regulates intracellular cAMP levels and PKA activation.
(31) Therefore, we first examined PKA activity in primary hepatocytes isolated from EP3 hep1/1 and EP3 hep-/-mice. Abruption of EP3 significantly increased PKA activity in primary hepatocytes, which was completely abolished by H89, a PKA inhibitor (Fig. 5A) . Next, we explored whether PKA directly phosphorylated HNF4a. Alignment of the HNF4a amino acid sequences of different species suggested that PKA phosphorylates the serine residue(s) in the "RRX/S" motif, which is highly conserved in vertebrates (Fig. 5B) . We conducted in vitro kinase assays using synthetic peptides containing residues 131-150 of wild-type HNF4a (HNF4a-WT) or mutant HNF4a with S142A or S143A (HNF4a-S142A or HNF4a-S143A), in which Ser142 or Ser143 was replaced with alanine, respectively. PKA was able to phosphorylate HNF4a-WT and HNF4a-S142A, but not HNF4a-S143A (Fig. 5C ). Using a phospho-(Ser/Thr) PKA substrate antibody, we observed increased PKAdependent phosphorylation of HNF4a in primary hepatocytes isolated from EP3
hep-/-mice, which was abolished by the PKA inhibitor, H89 (Supporting Fig. S7A ). To further confirm PKA-induced HNF4a phosphorylation, we developed an antibody that specifically recognizes the phosphorylated Ser143 site of HNF4a. Forskolin treatment dramatically increased Ser143 phosphorylation of HNF4a in WT mouse primary hepatocytes, which was completely abolished by H89 (Fig. 5D) . Infection with adenovirus expressing the HNF4a-S143A mutant (Ad-S143A) markedly increased the total level of HNF4a, but blocked Ser143 phosphorylation of HNF4a in primary mouse hepatocytes (Supporting Fig. S7B ). Furthermore, increased Ser143 phosphorylation of HNF4a and decreased expression of CYP7A1, CYP8B1, and CYP27A1 were observed in primary hepatocytes isolated from EP3
hep-/-mice, which were also abolished by H89 (Fig. 5E and Supporting Fig. S7C, left panel) . Similarly, EP3
hep-/-mice exhibited increased Ser143 phosphorylation of HNF4a in liver (Supporting Fig. S7D ). In addition, hepatic EP3 deficiency markedly increased cellular cholesterol in primary hepatocytes, which was completely abolished by H89 (Fig. 5E, right panel) . ChIP assay demonstrated that binding of HNF4a to the CYP7A1 promoter was markedly reduced in EP3
hep-/-hepatocytes, and H89 treatment blocked this effect (Fig. 5F ). Together, these data suggested that EP3 deficiency increases PKA-induced HNF4a phosphorylation at Ser143 and decreases the binding of HNF4a to the CYP7A1 promoter. INTERACTION INCREASES BA  BIOSYNTHESIS AND DECREASES  Chol IN EP3 hep-/-Ldlr 2/2 MICE As a proof of concept, we investigated whether disruption of the interaction between PKA and HNF4a can serve as a therapeutic means to lower Chol. Based on the structural motif involved in the interaction between PKA and HNF4a (Fig. 5C ), we designed a synthetic peptide (P121-170) containing amino acid residues 121-170 from the N terminus of HNF4a to compete with PKA and thus disrupt PKA-HNF4a interaction. As expected, P121-170 was able to abolish the increased Ser143 phosphorylation of HNF4a in HepG2 and Hep1-6 cells caused by EP3 antagonist L-798106 treatment (Supporting Fig. S8A mice ( Fig. 6B and Supporting Fig. S8C ). Likewise, the peptide increased plasma, liver, gallbladder, and fecal BAs to similar levels in both genotypes (Fig. 6C) (Fig. 6D,E) . Collectively, these data showed that disruption of interaction between PKA and HNF4a blocked the effects of hepatic EP3 deficiency on BA biosynthesis and cholesterol metabolism (Fig. 6F) 7A and Supporting Fig. S9 ). BA levels in plasma, liver, and gallbladder were greatly decreased, whereas fecal BA was increased, in EP3 hep-/-Ldlr 2/2 mice treated with resin (Fig. 7B) , consistent with a previous study. (32) Furthermore, resin treatment significantly decreased Chol levels in plasma and livers of EP3 hep1/1 Ldlr 2/2 and EP3 hep-/-Ldlr 2/2 mice, with no obvious difference between both groups (Fig. 7C ). Notably, fecal Chol level was significantly increased by resin (Fig. 7C) . Consequently, resin reduced the total en face aortic lesion area in both EP3 hep1/1 Ldlr 2/2 and EP3
INHIBITION OF PKA-HNF4a
hep-/-Ldlr 2/2 mice and eliminated the proatherogenic effects of hepatic EP3 deficiency (Fig. 7D,E) . Similarly, resin dramatically reduced lesion areas at aortic roots and abolished the effects of hepatic EP3 deficiency (Fig. 7F) . Thus, hepatic EP3 deficiency promotes WD-induced hypercholesterolemia and atherosclerosis by suppressing conversion of Chol to BAs through PKA/HNF4a-mediated inhibition of CYP7A1 expression.
Discussion
PGE 2 , one of the most abundant PGs in inflammation, displays both pro-and anti-inflammatory properties. (33) In this study, we found that PGE 2 receptor EP3 deficiency in hepatocytes causes hypercholesterolemia and, consequently, aggravates atherosclerosis in Ldlr -/-mice by suppressing hepatic BA biosynthesis. Mechanistically, we identified an EP3/PKA/HNF4a/ CYP7A1 signaling axis that controls BA biosynthesis and ultimately contributes to exacerbated hypercholesterolemia and atherosclerosis in EP3 hep-/-Ldlr 2/2 mice. PGE 2 is an important inflammatory mediator that has been implicated in promoting atherosclerosis development. (33) A previous study has shown increased expression of microsomal prostaglandin E synthesis-1 and EP3 receptor in peripheral blood mononuclear cells as well as in atherosclerotic plaques of patients, implying a direct involvement of PGE 2 /EP3 in atherogenesis. (34) However, the direct impacts of EP3 on development of atherosclerosis were not elucidated. Pharmacological inhibition or genetic deletion of EP3 reduced atherosclerosis-related thrombosis without increasing bleeding risk, (35) (36) (37) attenuated injury-induced arterial neointima formation, (38) and retarded hypoxia-induced pulmonary artery remodeling in mice. (39) However, our data demonstrated that EP3 deficiency in hepatocytes exacerbated atherosclerosis in hyperlipidemic mice through interruption of bile acid synthesis. Consistent with our observations, global EP3-deficient mice fed a highfat diet showed exaggerated ectopic lipid deposition in skeletal muscle and liver, with hepatic steatosis. (40) Moreover, EP3
2/2 mice are prone to diet-induced obesity. (40, 41) Thus, EP3 inhibition may not be a desirable strategy to suppress development of atherosclerosis, even though it inhibits atherosclerosis-related thrombosis.
The EP3 receptor couples to G ai to suppress PKA activity by lowering cellular cAMP. (33) We demonstrated that EP3 deletion or inhibition increased PKA activity in hepatocytes and resulted in elevated phosphorylation and reduced transcriptional activity of HNF4a that directly controls expression of CYP7A1, a rate-limiting enzyme in BA biosynthesis. In agreement with our observations, glucagon inhibits CYP7A1 expression by increasing cAMP/PKA activity in hepatocytes. (42) Changes in the expression of other key enzymes in BA biosynthesis, including CYP8B1, CYP27A1, and CYP7B1, followed trends similar to those of CYP7A1, likely because of accommodation to substrate changes caused by the alterations in CYP7A1 expression. (43) CYP7A1 overexpression restored the expression of these enzymes; however, it cannot be completely excluded that HNF4a may also directly govern the expression of the corresponding genes. (44) (45) (46) Moreover, HNF4a previously has been demonstrated to interact with other transcription factors such as pregnane X receptor, chicken ovalbumin upstream promoter-transcription factor II, and c-Jun, to regulate CYP7A1expression. (47) (48) (49) It remains to be further interrogated whether EP3-mediated HNF4a dephosphorylation interrupts recruitment of cotranscription factors.
Finally, we identified a specific PKA phosphorylation site in HNF4a. HNF4 harbors a consensus PKA phosphorylation motif (131-RRSS-134) within a region near its DNA-binding domain. (50) We pinpointed Ser143 of human HNF4a (equivalent to Ser143 of murine HNF4a) as the phosphorylation site of PKA. Mutation of Ser143, but not Ser142, abolished the phosphorylation of HNF4a by PKA. Importantly, this specific PKA phosphorylation site of HNF4a might serve as an important target for regulation of hepatic Chol metabolism. As a proof of concept, when Ser143 phosphorylation was blocked by
